<DOC>
	<DOCNO>NCT02012322</DOCNO>
	<brief_summary>Goal : The investigator propose test feasibility give supplement coenzyme Q10 ( Q10 ) improve symptoms subjective health age population . Rationale : Direct empirical evidence support benefit Q10 many symptom fatigue , muscle pain , cognition . In addition , Q10 also report benefit symptom include headache , sleep disturbance , breathe problem . This provide strong rationale test whether Q10 similar benefit symptom age population . Method : 44 age subject participate . The design 9 month , randomize , double-blind , placebo-controlled crossover study . Each subject `` cross '' high dose Q10 ( 300mg ) , low dose Q10 ( 100mg ) , placebo , receive agent 3 month period . Neither subject investigator know substance subject receive phase . Subjects randomly assign one six arm . Assessments : Assessments include feasibility study , subjective quality life , energy , metabolic lipid panel . Analyses show whether Q10 lead improvement compare placebo ; whether high Q10 dose improve outcome low dos ; whether people certain symptom characteristic get benefit people symptoms characteristic .</brief_summary>
	<brief_title>UCSD Q10 Aging Study</brief_title>
	<detailed_description>Goal : To determine feasibility double-blind placebo-controlled crossover study test whether coenzyme Q10 ( Q10 ) administration reduces symptom improve subjective health age population . Rationale : In number setting , study report benefit Q10 fatigue , muscle pain , cognition . Additionally Q10 defend mechanism may play role health problem age population . For reason , study evaluate benefit Q10 symptom quality life age population merit . Subjects : 44 subject age 55 older . Design : 9 month , randomize , placebo-controlled , double-blind crossover study . Analyses : Nonparametric secondarily parametric analysis compare effect Q10 v placebo ; high dose v low dose Q10 primary secondary endpoint . Possible effect modification ( differential benefit ) base factor oxidative state Q10 serum concentration explore regression analysis .</detailed_description>
	<mesh_term>Coenzyme Q10</mesh_term>
	<mesh_term>Ubiquinone</mesh_term>
	<criteria>Males female &gt; 55 year minimum 40 % female Willing fast 8 hrs prior blood draw Must able complete survey instrument assessment Must independent living Must community live Willing defer participation clinical trial till completion study participation . Agree abstain Q10containing product duration participation Women premenopausal capability conceive child Diagnosed HIV Diagnosed cancer ( except nonmelanoma skin cancer ) Diagnosed NYHA Stage 3 4 congestive heart failure Is currently take coumadin Can commit continue participation minimum 1 year Have take Q10 include dermal preparation last three month Due small number subject , special class ( include prisoner , institutionalized individual , may consider vulnerable population )</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Aging</keyword>
	<keyword>Coenzyme Q10</keyword>
	<keyword>Q10</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Mitochondrial Function</keyword>
	<keyword>Cell Energetics</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Ubiquinone</keyword>
</DOC>